lebrikizumab-lbkz 250 MG per 2 ML Pen Injector
- RxCUI
- 2693903
- RxNorm name
- lebrikizumab-lbkz 250 MG per 2 ML Pen Injector
- Display name
- lebrikizumab-lbkz 250 MG per 2 ML Pen Injector
- Full name
- lebrikizumab-lbkz 250 MG per 2 ML Pen Injector
- Term type
- SY
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:05
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761306 | Ebglyss | lebrikizumab-lbkz | 351(a) | Rx | 2026-09-01 |
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| EBGLYSS | LEBRIKIZUMAB-LBKZ | Eli Lilly and Company | 7a774ea2-acde-4aaa-9a8f-ccba5a5b1d5f | 2026-06-09 | Warnings, Adverse reactions | 2693903 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 7a774ea2-acde-4aaa-9a8f-ccba5a5b1d5f | lebrikizumab-lbkz 250 MG in 2 ML Pen Injector [PSN] · 2 ML lebrikizumab-lbkz 125 MG/ML Pen Injector [SCD] · lebrikizumab-lbkz 250 MG per 2 ML Pen Injector [SY] | 3 | 12 | These highlights do not include all the information needed to use EBGLYSS safely and effectively. See full prescribing information for EBGLYSS. EBGLYSS (lebrikizumab-lbkz), injection, for subcutaneous use Initial U.S. Approval: 2024 | 20260520 |